For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

“The ACCESS and ACCESS II studies are designed to generate a comprehensive data set that we believe will provide additional insights into the differentiated profile of GSBR-1290 as a potential best-in ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

They include MET-233i, an injectable amylin analog that is Metsera’s answer to the sector’s search for a once-monthly dosing ...

Metsera has developed its proprietary MOMENTUM™ platform to optimize oral delivery of NuSH analog peptides and is advancing multiple GLP-1 RA peptides with potential best-in-class bioavailability ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

84th Scientific Sessions supporting TERN-501 in combination with a GLP-1 receptor agonist for obesity Preclinical findings demonstrated TERN-501 in combination with semaglutide significantly enhanced ...

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency ... as an add-on to GLP-1s for further improvement of weight loss or to ...